Crossref
26-A-20358-ACC ATRIAL FIBRILLATION WITHOUT HEART FAILURE: CAN SGLT2 INHIBITORS IMPROVE PROGNOSIS?
JACC · 2026-04 · 87 (13) · A134
DOI: 10.1016/j.jacc.2026.02.338 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Krutagni Adwait A. Mehta und 5 weiteren Autor:innen.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Mehta, K. A. A., Tated, R. C., Elias, S., Badam, S., Feroze, R., & Arora, S. (2026). 26-A-20358-ACC ATRIAL FIBRILLATION WITHOUT HEART FAILURE: CAN SGLT2 INHIBITORS IMPROVE PROGNOSIS?. JACC, 87(13), A134. https://doi.org/10.1016/j.jacc.2026.02.338
Vancouver
Mehta KAA, Tated RC, Elias S, Badam S, Feroze R, Arora S. 26-A-20358-ACC ATRIAL FIBRILLATION WITHOUT HEART FAILURE: CAN SGLT2 INHIBITORS IMPROVE PROGNOSIS?. JACC. 2026;87(13):A134. doi:10.1016/j.jacc.2026.02.338
BibTeX
@article{Mehta2026,
author = {Mehta, Krutagni Adwait A. and Tated, Ritu C. and Elias, Sameh and Badam, Shruthi and Feroze, Rafey and Arora, Shilpkumar},
title = {26-A-20358-ACC ATRIAL FIBRILLATION WITHOUT HEART FAILURE: CAN SGLT2 INHIBITORS IMPROVE PROGNOSIS?},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A134},
doi = {10.1016/j.jacc.2026.02.338}
}
EUVIMED